We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Benevolent AI (BAI) EUR1 A

Sell:€0.75 Buy:€0.78 Change: €0.03 (4.00%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
Change: €0.03 (4.00%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
Change: €0.03 (4.00%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

BenevolentAI SA is an artificial intelligence (AI)-enabled drug discovery and development company. Through the combined capabilities of this AI platform, its scientific expertise, and wet-lab facilities, it delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers its in-house drug pipeline and supports collaborations with AstraZeneca, as well as research and charitable institutions. Its pipeline includes BEN-2293, BEN-8744, BEN-9160 and BEN-28010. It integrates data from across domains and data types, including omics, molecules, experiments, literature, pathology and biological systems to provide a holistic view of biology. BEN-8744 is under development as an ulcerative colitis treatment for a novel target discovered using its AI platform. BEN-2293 is a topical PanTrk inhibitor in development to relieve inflammation and rapidly resolve itch in patients with atopic dermatitis.

Contact details

4-8 Maple Street
United Kingdom
+ ()

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€111.14 million
Shares in issue:
117.49 million
Euronext Amsterdam

Key personnel

  • Francois Nader
    Chairman of the Board
  • Joerg Moeller
    Chief Executive Officer, Executive Director
  • Catherine Isted
    Chief Financial Officer
  • Christina Busmalis
    Chief Revenue Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.